ArticleAnalytical and bioanalytical chemistry2025
Deciphering disease-specific glycosylation: unraveling diabetes subtypes through serum glycopattern.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein glycosylation profiling in lung adenocarcinoma and precursor lesions: analysis of FFPE tissue sections.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of diabetes that develops in adulthood, characterized by autoimmune destruction of pancreatic β-cells and subsequent insulin deficiency, akin to type 1 diabetes (T1D). Due to its shared genetic, immunological, and metabolic features with both T1D and type 2 diabetes (T2D), LADA is frequently misdiagnosed and inappropriately treated as T2D. To address this, we developed the A.NG algorithm, which identifies serum glycopatterns by calculating the ratio of upregulated to downregulated N-glycans, thereby facilitating the detection of subtle glycan alterations specific to each diabetes subtype. Our method, which utilizes matrix-assisted laser desorption ionization (MALDI) for N-glycan profiling, revealed distinct glycan patterns across T1D, T2D, and LADA, with observed correlations achieving an AUC of 0.918 in this cohort. While these findings demonstrate the technical feasibility of detecting subtype-associated glycosylation changes, their clinical utility for subtype differentiation requires validation in larger studies with refined quantification approaches. Furthermore, complementary ELISA and intact glycopeptide analyses showed that enzymes like FUT8 and FUCA1 contribute to altered glycan expression patterns on specific glycoproteins, which could serve as potential biomarkers for LADA. In conclusion, the A.NG algorithm represents a promising novel approach for distinguishing between LADA and T1D or T2D, with the potential to significantly improve the diagnosis and management of these diabetes subtypes.
Indexed as
Identifiers
40914764What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.